Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Profound Medical (PROF) Capital Leases (2021 - 2022)

Profound Medical has reported Capital Leases over the past 2 years, most recently at $2.6 million for Q3 2022.

For Q3 2022, Capital Leases changed N/A year-over-year to $2.6 million; the TTM value through Sep 2022 reached $2.6 million, changed N/A, while the annual FY2021 figure was $3.6 million, N/A changed from the prior year.
Capital Leases for Q3 2022 was $2.6 million at Profound Medical, down from $3.7 million in the prior quarter.
Over five years, Capital Leases peaked at $3.7 million in Q1 2022 and troughed at $2.6 million in Q3 2022.